{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=69",
    "query": {
      "intervention": "Placebo- C",
      "page": 69
    },
    "page_size": 10
  },
  "pagination": {
    "page": 69,
    "page_size": 10,
    "total_count": 1838,
    "total_pages": 184,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=70&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=68&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T14:52:30.389Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01325415",
      "title": "A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Amount of NKTR-118 in Blood",
        "Variation in the Heart's Electrical Cycle"
      ],
      "interventions": [
        {
          "name": "NKTR-118",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 45,
      "start_date": "2011-04",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2014-10-15",
      "last_synced_at": "2026-11-09T14:52:30.389Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01325415"
    },
    {
      "nct_id": "NCT06891443",
      "title": "Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Leber Congenital Amaurosis 10",
        "Blindness",
        "Leber Congenital Amaurosis",
        "Sensation Disorders",
        "Vision Disorder",
        "Neurological Manifestations",
        "Eye Diseases, Hereditary",
        "Eye Diseases",
        "Eye Disorders Congenital",
        "Retinal Disease"
      ],
      "interventions": [
        {
          "name": "sepofarsen",
          "type": "DRUG"
        },
        {
          "name": "Placebo IVT",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Laboratoires Thea",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2025-06-04",
      "completion_date": "2028-10",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-09T14:52:30.389Z",
      "location_count": 5,
      "location_summary": "San Francisco, California • Miami, Florida • Iowa City, Iowa + 2 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06891443"
    },
    {
      "nct_id": "NCT02052726",
      "title": "A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clostridium Difficile"
      ],
      "interventions": [
        {
          "name": "C. difficile vaccine with adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 184,
      "start_date": "2014-01-22",
      "completion_date": "2015-05-05",
      "has_results": false,
      "last_update_posted_date": "2018-12-04",
      "last_synced_at": "2026-11-09T14:52:30.389Z",
      "location_count": 6,
      "location_summary": "Overland Park, Kansas • Cary, North Carolina • Raleigh, North Carolina + 2 more",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Cary",
          "state": "North Carolina"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02052726"
    },
    {
      "nct_id": "NCT05096403",
      "title": "A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cold Agglutinin Disease"
      ],
      "interventions": [
        {
          "name": "Pegcetacoplan",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching Pegcetacoplan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Swedish Orphan Biovitrum",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2022-10-20",
      "completion_date": "2024-09-11",
      "has_results": true,
      "last_update_posted_date": "2025-10-30",
      "last_synced_at": "2026-11-09T14:52:30.389Z",
      "location_count": 5,
      "location_summary": "Whittier, California • Miami Lakes, Florida • Iowa City, Iowa + 2 more",
      "locations": [
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Greenville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05096403"
    },
    {
      "nct_id": "NCT02442687",
      "title": "JKB-121 for the Treatment of Nonalcoholic Steatohepatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "JKB-121: 5 mg twice daily",
          "type": "DRUG"
        },
        {
          "name": "JKB-121: 10 mg twice daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Manal Abdelmalek",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 65,
      "start_date": "2015-08-01",
      "completion_date": "2017-09-24",
      "has_results": true,
      "last_update_posted_date": "2019-01-07",
      "last_synced_at": "2026-11-09T14:52:30.389Z",
      "location_count": 8,
      "location_summary": "Dothan, Alabama • Chicago, Illinois • Las Vegas, Nevada + 5 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02442687"
    },
    {
      "nct_id": "NCT04753606",
      "title": "Randomized Study of Obicetrapib as an Adjunct to Statin Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidemias",
        "High Cholesterol",
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Obicetrapib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 120,
      "start_date": "2021-02-18",
      "completion_date": "2021-08-30",
      "has_results": true,
      "last_update_posted_date": "2024-07-12",
      "last_synced_at": "2026-11-09T14:52:30.389Z",
      "location_count": 19,
      "location_summary": "Anniston, Alabama • Huntington Park, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04753606"
    },
    {
      "nct_id": "NCT00249704",
      "title": "Randomized Study Of Exercise And Vitamin D In Frail Elderly Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Elderly, Frail"
      ],
      "interventions": [
        {
          "name": "Vitamin D + Sham Exercise",
          "type": "DRUG"
        },
        {
          "name": "Vitamin D Placebo + Exercise",
          "type": "PROCEDURE"
        },
        {
          "name": "Vitamin D Placebo + Sham Exercise",
          "type": "PROCEDURE"
        },
        {
          "name": "Vitamin D + Exercise",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "75 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "75 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2005-10",
      "completion_date": "2008-01",
      "has_results": false,
      "last_update_posted_date": "2009-01-08",
      "last_synced_at": "2026-11-09T14:52:30.389Z",
      "location_count": 4,
      "location_summary": "Farmington, Connecticut • Hyattsville, Maryland • Roslindale, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Hyattsville",
          "state": "Maryland"
        },
        {
          "city": "Roslindale",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00249704"
    },
    {
      "nct_id": "NCT00800007",
      "title": "Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "ANZ-521",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anza Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 5,
      "start_date": "2008-11",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2009-02-20",
      "last_synced_at": "2026-11-09T14:52:30.389Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • San Antonio, Texas",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00800007"
    },
    {
      "nct_id": "NCT02501811",
      "title": "Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ischemic Cardiomyopathy"
      ],
      "interventions": [
        {
          "name": "Mesenchymal Stem Cells (MSC)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "c-kit+ cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (Plasmalyte A)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "21 Years to 79 Years"
      },
      "enrollment_count": 125,
      "start_date": "2015-10",
      "completion_date": "2020-07-22",
      "has_results": true,
      "last_update_posted_date": "2021-04-26",
      "last_synced_at": "2026-11-09T14:52:30.389Z",
      "location_count": 7,
      "location_summary": "Stanford, California • Gainesville, Florida • Miami, Florida + 4 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02501811"
    },
    {
      "nct_id": "NCT02280044",
      "title": "Efficacy of Rifaximin in Preventing Campylobacteriosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Dysentery",
        "Diarrhea",
        "Enteric Campylobacteriosis"
      ],
      "interventions": [
        {
          "name": "Rifaximin intervention",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo intervention",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Johns Hopkins Bloomberg School of Public Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-10",
      "completion_date": "2016-08-09",
      "has_results": true,
      "last_update_posted_date": "2018-11-20",
      "last_synced_at": "2026-11-09T14:52:30.389Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02280044"
    }
  ]
}